|
|
 |
|
Viewing report
|
|
|
|
Pipeline Insight: Rheumatoid Arthritis and Osteoarthritis - Striving for innovation among me-toos
Datamonitor, Feb 2003, Pages: 185
Introduction
Driven by the globally aging population, the incidence of OA and RA will increase significantly over the next seven years. The efforts to find cures for these diseases will increase as a direct result of this growing patient potential. The arthritis market will reach nearly $21bn by 2010, presenting abundant opportunity for the manufacturers of innovative and efficacious drugs to gain profits.
The majority of product development is being seen in the Dmard class with a number of mechanisms of action being investigated as alternatives to current treatments. The Cox-ii market segment is becoming increasingly crowded, but only pipeline products that are sufficiently differentiated will be successful. This Pipeline Analysis identifies development compounds with the greatest sales potential, and opportunities for marketing and licensing collaborations. Recommendations for improved clinical trial design and strategies to best satisfy unmet need in OA and RA treatment are discussed, based on exclusive opinion leader research.
Scope
- Analysis of clinical trial design in OA and RA, with opinion leader-driven recommendations for improvements in this area
- Case studies examining the strategies of all of the major players in the OA and RA markets
- Comparative analysis and forecasted sales for the key late stage Dmards and Nsaids
- Opinion leader driven analysis of early stage (pre-clinical and phase I) pipeline OA and RA drugs
Report Highlights
Of the large number of late-stage Dmards set to enter the market between 2003 and 2006, Genentech/Idec/Roche’s rituximab and Celltech/Pfizer/Pharmacia’s Cdp-870 are set to have the greatest impact and highest potential of dethroning the current market leaders, Enbrel and Remicade.
The similarity between 2nd generation Cox-ii inhibitors, and the fact that there are no major patent expiries in the forecast window, will ensure that Celebrex and Vioxx retain their dominance of the pain market, with lumiracoxib being the most promising pipeline Nsaid for the treatment of arthritis and licofelone being slightly less promising.
Strategically designed clinical trials represent a key area which companies with pipeline OA and RA drugs can use to maximize potential. The highest levels of unmet need are in effective endpoint selection, clinical trial duration and comparator drug selection. Improvement in any of these areas will offer new compounds an edge over the competition.
Reasons to Purchase
- Identify which pipeline compounds have the highest potential and which pose the least threat to current market leaders
- Target R&D resources more effectively through a better understanding of unmet needs and the impact of important recent clinical trials
- Enhance both your market entry and product defense strategies through opinion leader recommendations regarding unmet needs and clinical trial design
Customers who bought this item also bought
Drugs of Tomorrow 2002: Arthritis
Pipeline Insight: Disease Modification in Rheumatoid Arthritis - New drug targets compete in crowded market
The Rheumatoid Arthritis Market - Competitive Landscape and Clinical Stage Analysis
Commercial and Pipeline Perspectives: Rheumatoid Arthritis - Novel Biologics Drive Innovation in the Global RA Market
Drugs of Tomorrow 2000: Arthritis - Developments For a Competitive Market
Treatment Algorithms: Rheumatoid Arthritis 2nd Edition - Dmards Move to Front of Pack
Pipeline Insight: Disease Modification In Rheumatoid Arthritis - Competition For The Anti-TNF Failure Patient Population Increases
Market Dynamics: Arthritis - The Ongoing Battle for Supremacy
Osteoarthritis and Rheumatoid Arthritis: Opinion Leader Forum - Expert's Views and Perspectives on Diagnosis, Treatment, Product Performance and Closing the Need Gap
Arthritis in the United States
Stakeholder Insight: Rheumatoid Arthritis - DMARDs Gain Ground as Biologics Competition Intensifies
Disease Modification In Rheumatoid Arthritis - Pipeline Uptake Inhibited By Anti-Tnfs
|
|
|
|
